Fortress Biotech

Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Fortress Biotech (FBIO) delivered earnings and revenue surprises of 71.43% and 29.11%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Fortress Biotech (FBIO) Reports Q2 Loss, Tops Revenue Estimates

Net revenue for second quarter of 2021 increased 89% year-over-year to $17.8 million, a quarterly record

Fortress Biotech Reports Record Second Quarter 2021 Financial Results and Recent Corporate Highlights

Fortress Biotech (FBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Fortress Biotech (FBIO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

The FDA refused to approve IV tramadol for the second time.

Why Fortress Biotech Stock Is Sinking Today

CytRx

Mustang Bio

MEI Pharma

Matinas BioPharma Hlds

Orphazyme A/S

Penny stocks to watch with upcoming event dates to keep in mind this week The post Best Penny Stocks To Buy? 4 To Watch This Week With Potential Catalysts appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks To Buy? 4 To Watch This Week With Potential Catalysts

Aptose Biosciences

Regulus Therapeutics

These penny stocks are expecting to release key information this month. The post Biotech Penny Stocks To Watch For June 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Biotech Penny Stocks To Watch For June 2021

The following article is sponsored by the clinical communications unit of Redington, Inc. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only. Fortress Biotech (NASDAQ: FBIO) creates partner companies to manage and optimize cancer immunotherapy and other disease treatment development programs.

Diversifying to Conquer: Fortress Biotech (FBIO) Partnering Expansion Driving Progress in Cancer Immunotherapy and Rare Disease Therapeutics

NEW YORK, June 01, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in three virtual investor conferences in June 2021.

Fortress Biotech to Participate in Three June 2021 Virtual Investor Conferences

Rolling NDA submission for CUTX-101 for the treatment of Menkes disease is expected to begin in the second half of 2021

REPEAT -- Fortress Biotech Reports First Quarter 2021 Financial Results and Recent Corporate Highlights

Fortress Biotech Reports First Quarter 2021 Financial Results and Recent Corporate Highlights

AvroBio Inc

BeyondSpring

Beyond Air Inc

Let us take a look at some drug/biotech stocks that are poised to beat on first-quarter earnings.

4 Biotech Stocks Set to Outpace Q1 Earnings Estimates

Agreement signed with Fuji Yakuhin to develop Dotinurad, a potential best-in-class urate transporter (URAT1) inhibitor for gout and potentially other hyperuricemic indications including chronic kidney disease and heart failure

Fortress Biotech Announces Exclusive License Agreement With Fuji Yakuhin to Develop Dotinurad in North America and Europe

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Zacks Earnings ESP: A Better Way to Find Earnings Surprises for Medical

FBIO is a conglomerate with numerous partners and a vast pipeline.

Fortress Bio: Interesting Model Of Doing Medicine

Abeona Therapeutics

Synlogic

Penny stocks are very risky, which is why they have such low prices. Many of the companies in this risky part of the market will go bankrupt.

3 Penny Stocks That Wall Street Wants You To Buy Now

CTI BioPharma

Energy Focus

ION Geophysical

Pixelworks

Many penny stocks are destined for bankruptcy, but there are some that will survive. Wall Street thinks these companies are undervalued.

7 Penny Stocks That May Not Be Penny Stocks For Long

Investors need to pay close attention to Fortress Biotech (FBIO) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Fortress Biotech (FBIO) Stock?

Fortress Biotech (FBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Fortress Biotech (FBIO) Surges 11.5%: Is This an Indication of Further Gains?

The stock price of Fortress Biotech (NASDAQ: FBIO) increased by over 10% pre-market. This is why it happened.

FBIO Stock: Over 10% Increase Pre-Market Explanation

NEW YORK, April 07, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in the 20th Annual Needham Virtual Healthcare Conference, taking place April 12-15, 2021. The company will present on Monday, April 12, 2021, at 4:30 p.m. ET and will also participate in one-on-one meetings during the conference. A webcast of the company's presentation will be available on the Events page under the News & Media section of Fortress' website: www.fortressbiotech.com for approximately 30 days following the presentation.

Fortress Biotech to Participate in the 20th Annual Needham Virtual Healthcare Conference

SCOTTSDALE, Ariz. and NEW YORK, April 05, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”), a partner company of Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), today announced that it has entered into an agreement with East West Bank (“EWB”) in which EWB will provide a $7.5 million working capital line of credit.

Journey Medical Corporation Enters $7.5 Million Line of Credit Agreement with East West Bank

Fortress Biotech Inc's (NASDAQ: FBIO) partner company Journey Medical Corporation has agreed to acquire Qbrexza (glycopyrronium) in the U.S. from Dermira Inc, a wholly-owned subsidiary of Eli Lilly And Co (NYSE: LLY). The transaction is expected to close early in the second quarter of this year.

Fortress Biotech's Partner Firm Expands Footprint In Dermatology With Qbrexza Acquisition

The first and only prescription cloth towelette approved to treat primary axillary hyperhidrosis in people nine-years of age and older is Journey Medical's seventh marketed dermatology product The first and only prescription cloth towelette approved to treat primary axillary hyperhidrosis in people nine-years of age and older is Journey Medical's seventh marketed dermatology product

Journey Medical Corporation Enters into a Definitive Agreement with Dermira, Inc., a Wholly-Owned Subsidiary of Eli Lilly and Company, to Acquire QBREXZA®

Revenue from marketed dermatology products increased 28% for full-year 2020 compared to 2019

Fortress Biotech Reports Record 2020 Financial Results and Recent Corporate Highlights

Accutane is Journey Medical's sixth marketed dermatology product Accutane is Journey Medical's sixth marketed dermatology product

Fortress Biotech's Partner Company, Journey Medical Corporation, In-licenses and Launches Accutane® for the Treatment of Severe Recalcitrant Nodular Acne

News for Fortress Biotech Stock (FBIO)